Research presented at the EASD annual meeting in Madrid found that semaglutide and tirzepatide, approved drugs for type 2 diabetes and weight loss, led to significant weight loss and improved blood sugar control in individuals with type 1 diabetes who are overweight or obese. The study, conducted at a US diabetes clinic, showed that patients treated with these drugs lost more weight compared to controls. Additionally, those taking tirzepatide were able to reduce their insulin dose, indicating improved insulin resistance. The researchers suggest that these drugs could be a valuable addition to insulin therapy for type 1 diabetes patients with overweight or obesity, but further trials are needed for evaluation.
Source link
Semaglutide and tirzepatide lead to better blood sugar control and weight loss in type 1 diabetes, study finds
